Evaxion Posts Three-Year Data for Personalized Melanoma Vaccine EVX-01
Evaxion Biotech reports three-year follow-up data for EVX-01, its AI-designed personalized therapeutic vaccine for melanoma, extending durability evidence.
Topic
Evx 01
Topic
Evx 01
Evaxion Reports Three-Year Data for Melanoma Vaccine EVX-01
Evaxion reports three-year data for melanoma vaccine EVX-01, a personalized neoantigen candidate; the disclosure headline omits s…
Evaxion Brings Three-Year EVX-01 Melanoma Data to ESMO 2026
Evaxion will present three-year Phase 2 follow-up on its personalized neoantigen vaccine EVX-01 in advanced melanoma at ESMO 2026…
Evaxion to Present New EVX-01 Immune Data at SITC 2026
Evaxion will present comprehensive immune profiling of EVX-01 plus pembrolizumab at SITC on Nov. 6–7, after a 75% two-year ORR in…